The ELN 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates re-classification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood.2024026925 | DOI Listing |
Publication Analysis
Top Keywords
eln 2024
8
refined eln
4
2024 risk
4
risk stratification
4
stratification improves
4
improves survival
4
survival prognostication
4
prognostication venetoclax-based
4
venetoclax-based therapy
4
therapy aml
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!